Depression, a common neurological condition, is one of the leading causes of disability and suicide worldwide. Standard treatment, targeting monoamine transporters selective for the neurotransmitters serotonin and noradrenaline, is not able to help many patients that are poor responders. This study advances the development of sazetidine-A analogues that interact with α4β2 nicotinic acetylcholine receptors (nAChRs) as partial agonists and that possess favorable antidepressant profiles. The resulting compounds that are highly selective for the α4β2 subtype of nAChR over α3β4-nAChRs are partial agonists at the α4β2 subtype and have excellent antidepressant behavioral profiles as measured by the mouse forced swim test. Preliminary absorption, distribution, metabolism, excretion, and toxicity (ADMET) studies for one promising ligand revealed an excellent plasma protein binding (PPB) profile, low CYP450-related metabolism, and low cardiovascular toxicity, suggesting it is a promising lead as well as a drug candidate to be advanced through the drug discovery pipeline.
Depression, a commonn class="Disease">neurological condition, is one of the leading causes of disability and suicide worldwide. Standard treatment, targeting monoamine transporters selective for the neurotransmitters serotonin and noradrenaline, is not able to help many patients that are poor responders. This study advances the development of sazetidine-A analogues that interact with α4β2 nicotinic acetylcholine receptors (nAChRs) as partial agonists and that possess favorable antidepressant profiles. The resulting compounds that are highly selective for the α4β2 subtype of nAChR over α3β4-nAChRsare partial agonists at the α4β2 subtype and have excellent antidepressant behavioral profiles as measured by the mouse forced swim test. Preliminary absorption, distribution, metabolism, excretion, and toxicity (ADMET) studies for one promising ligand revealed an excellent plasma protein binding (PPB) profile, low CYP450-related metabolism, and low cardiovascular toxicity, suggesting it is a promising lead as well as a drug candidate to be advanced through the drug discovery pipeline.
Authors: Yi Fan; Rayomand Unwalla; Rajiah A Denny; Li Di; Edward H Kerns; David J Diller; Christine Humblet Journal: J Chem Inf Model Date: 2010-06-28 Impact factor: 4.956
Authors: Alan P Kozikowski; J Brek Eaton; Krishna Mohan Bajjuri; Sheela K Chellappan; Yihua Chen; Sudhakar Karadi; Rong He; Barbara Caldarone; Michael Manzano; Po-Wai Yuen; Ronald J Lukas Journal: ChemMedChem Date: 2009-08 Impact factor: 3.466
Authors: Barbara J Caldarone; Daguang Wang; Neil E Paterson; Michael Manzano; Allison Fedolak; Katie Cavino; Mei Kwan; Taleen Hanania; Sheela K Chellappan; Alan P Kozikowski; Berend Olivier; Marina R Picciotto; Afshin Ghavami Journal: Psychopharmacology (Berl) Date: 2011-04-13 Impact factor: 4.530
Authors: Annamaria Lilienkampf; Marco Pieroni; Baojie Wan; Yuehong Wang; Scott G Franzblau; Alan P Kozikowski Journal: J Med Chem Date: 2010-01-28 Impact factor: 7.446
Authors: Subhasish Tapadar; Rong He; Doris N Luchini; Daniel D Billadeau; Alan P Kozikowski Journal: Bioorg Med Chem Lett Date: 2009-04-20 Impact factor: 2.823
Authors: Hankun Zhang; Werner Tückmantel; J Brek Eaton; Po-Wai Yuen; Li-Fang Yu; Krishna Mohan Bajjuri; Allison Fedolak; Daguang Wang; Afshin Ghavami; Barbara Caldarone; Neil E Paterson; David A Lowe; Daniela Brunner; Ronald J Lukas; Alan P Kozikowski Journal: J Med Chem Date: 2012-01-10 Impact factor: 7.446
Authors: Yang Yuan; Li-Fang Yu; Xi Qiu; Alan P Kozikowski; Richard B van Breemen Journal: J Chromatogr B Analyt Technol Biomed Life Sci Date: 2012-11-23 Impact factor: 3.205
Authors: Li-Fang Yu; J Brek Eaton; Han-Kun Zhang; Emily Sabath; Taleen Hanania; Guan-Nan Li; Richard B van Breemen; Paul Whiteaker; Qiang Liu; Jie Wu; Yong-Chang Chang; Ronald J Lukas; Dani Brunner; Alan P Kozikowski Journal: Pharmacol Res Perspect Date: 2014-03-12